Cyrus Biotechnology featured in BIOCENTURY article on de novo Protein Design Revolution

SEATTLE, WA July 29, 2019 — Cyrus Biotechnology, Inc., a Seattle-based biotech software company commercializing Rosetta, the most advanced computational protein design platform, has been mentioned in the BIOCENTURY’s article: Institute for Protein Design’s de novo revolutionHow a Seattle hub is overhauling protein- and cell-based therapies by breaking free o evolution’s constraints. The BIOCENTURY article can be found here. About Cyrus Biotechnology Cyrus Biotechnology, Inc. is a privately-held biotechnology software company offering Cyrus Bench®, a SaaS platform for protein engineering to accelerate discovery of biologics and small molecules for the Biotechnology, Pharmaceutical, Chemical, Consumer Products and Synthetic Biology industries. Cyrus Bench® is based on the Rosetta software from Prof. David Baker’s laboratory at the University of Washington, the most powerful protein engineering software available. Cyrus customers include 12 of the top 20 Global Pharmaceutical firms and is financed by leading investors in both Technology and Biotechnology, including Trinity Ventures, Orbimed, Springrock Ventures, Alexandria Venture Investments, and W Fund.

Share this post